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The implications of circulating essential fatty acids (FA) on the inflammatory risk profile and
clinical outcome are still unclear. In order to gain a deeper understanding of the role of
polyunsaturated fatty acids (PUFA) in the pathogenesis of acute infection, we analyzed the
FA content in red blood cell (RBC) membranes of patients with Clostridium difficile
infection (CDI) and controls. We prospectively studied 60 patients including 30 patients with
CDI and 30 controls to assess lipid concentrations in erythrocyte membranes using gas
chromatography. We observed a higher level of saturated fatty acids (SFA) in RBC
membranes from patients with CDI. In patients with CDI, we also noticed a higher level of
20:4 n-6 FA and only a small amounts of C20:2n-6, C20:3n-6 FAs, arachidonic acid (AA)
precursors, which suggest an intense inflammatory reaction in the organism during infection.
We also noticed low levels of n-3 FA in the RBC membranes of patients infected with CDI.
There is a deficit of n-3 FA in patients with CDI. n-3 FA are probably used during CDI as
precursors of pro-resolving mediators that may indicate a therapeutic role of n-3 PUFAs in
CDI. The changes in fatty acids in erythrocyte membranes during CDI alter their functions
which may have an impact on the clinical outcome.
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Clostridium difficile infection (CDI) is a disease
of the gastrointestinal tract caused by an anaerobic
gram-negative rod- order: Eubacteriales, fam-
ily: Baciliaceae, genus: Clostridium, species: dif-
ficile. The main symptoms of this infection include
diarrhea of varying intensity accompanied by ab-
dominal pain and fever (TEDESCO et al. 1974).
Mortality in the course of CDI ranges from 6% to
38% depending on patient age or comorbid condi-
tions (MITCHELL & GARDNER 2012). Unexpect-
edly, CDI has become one of the most prominent
nosocomial infections of the past 20 years. Par-
ticularly disturbing is the increase in incidence,
mortality, and recurrence of this infection. The
pathogenesis of CDI is complex and still not fully
understood, however a number of recent studies
have furthered scientific knowledge in this area
(SURAWICZ 2013; GOUDARZI et al. 2014).
Lipids play an important biological role which
goes far beyond their function as storage of en-
ergy. They are important intercellular messengers,
they influence gene expression, and are also me-
diators that take part in the inflammatory reaction
(NOWAK 2010; HOFMANOVA et al. 2014). Vari-
ous derivatives of fatty acids (FA) are formed dur-
ing the course of both physiological and
pathological metabolic processes, often with dif-
ferent functions (HOFMANOVA et al. 2014). Poly-
unsaturated fatty acids (PUFA) are an important
dietary element as they are synthesized from their
precursors:18:3n-3 and 18:2n-6 essential FAs by
the human body (NOWAK 2010). The subsequent
formation of further FA is carried out via down-
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stream metabolic processes and depends on many
factors such as the presence of lipid-influencing
enzymes, cooperation of blood cells, endothelium,
epithelium, or membrane receptors (HOFMANOVA
et al. 2014). At this cellular and tissue level, host
factors and environmental influence, such as diet,
combines individually and leads to the diversity of
each individual. The analysis of membrane lipid
composition in red blood cell (RBC) provides a
simple, suitable model for studying FA metabo-
lism. Moreover some changes in the lipid layer of
RBC membranes alter their fluidity which may
contribute to clinical problems (MARTINELLI et al.
2008; SIENER et al. 2010; RAPHAEL & SORDILLO
2013; TAKKUNEN et al. 2013).
In an earlier study we noticed for the first time
that acute infection of the gastrointestinal tract
with Clostridium difficile (C. diff.) is associated
with abnormalities in rheological properties of
blood, as well as increased aggregation of RBCs,
which correlated with severity of inflammation
(CZEPIEL et al. 2014). Therefore we continued this
study associated with potential erythrocyte mem-
brane changes during CDI infection. We prospec-
tively studied the FA content of RBC cell
membranes in patients with CDI and controls.
Material and Methods
Abrreviations used in the text
AA, arachidonic acid; AI, Aggregation Index;
BHT, butylated hydroxytoluene; BMI, body mass
index; CDI, Clostridium difficile infection; C.
diff., Clostridium difficile; COX-2, cyclooxyge-
nase 2; DSS, dextran sulfate sodium; DHA, doco-
sahexaenoic acid; EI, Elongation Index; EPA,
eicosapentaenoic acid; FA, fatty acids; FAME,
fatty acid methyl esters; IL-10, interleukin 10;
HUS, hemolitic uremic syndrome; LA, linoleic
acid; MUFA, monounsaturated fatty acids; PGE2,
prostaglandin E2 ;PUFA, polyunsaturated fatty ac-
ids; RBC, red blood cells; SD, standard deviation;
SFA, saturated fatty acids; UNSFA, unsaturated
fatty acids.
Patients
The study was conducted in accordance with the
Declaration of Helsinki (1975) and approved by
the Local Ethics Committee (KBET/6/B/2014).
We prospectively studied 60 patients. The study
group included 30 patients with CDI (19 women
and 11 men) hospitalized at the Department of In-
fectious Diseases, Jagiellonian University Hospi-
tal in Kraków, aged from 23 to 93 years (median:
64 years), with median body mass index (BMI)
24.3 kg/m2 and 30 volunteers as control group (18
women and 12 men) from 32 to 85 years old (me-
dian: 61.3 years), with median BMI 24.0 kg/m2.
The diagnosis of C. diff. was based on history, epi-
demiological data, physical examination, and
laboratory tests. CDI was diagnosed in patients ex-
periencing diarrhea, defined as the passage of 3 or
more unformed stools in 24 hours; the infection
was then confirmed by the detection of the C. diff.
antigen and toxins in feces using the C. diff. Quick
Check Complete test kit (TechLab Inc., Blacks-
burg, USA). When the test came back positive for
the antigen but negative for the toxin, the test for
the C. diff. toxin was repeated with the ELISA C.
diff. toxin A/B II test kit (TechLab Inc., Blacks-
burg, USA) or by genetic methods, Illumigene C.
diff. (Meridian, Bioscience, Inc., Cincinnati,
USA). All microbiological tests were performed in
the Microbiology Department, University Hospi-
tal in Kraków. Patients were questioned about
their diet. Each patient who actively modified
his/her diet was excluded, for example: using en-
ergy drinks, abuse of alcohol, vegan/vegetarian
diet, or diabetic diet. We also excluded patients on
a reduction diet. All participants described their
diet as typical. Exclusion criteria included the
presence of any other acute or chronic inflamma-
tory diseases in both groups and diarrhea from any
reason in controls.
Sample collection
Venous blood samples were collected in
K2-EDTA-containing tubes. The first sample was
taken no later than 48 hours after initiating ther-
apy, when the therapeutic effect of the antibiotic
was not yet fully realized and patients still mani-
fested clinical symptoms.
Erythrocytes were separated from plasma by
centrifugation (1500 × g, for 10 min) and washed
with phosphate buffer saline. 10 µl of 0.05 % buty-
lated hydroxytoluene (BHT) was added to each
sample.
Reagents used for gas chromatography
BHT, 14 % BF3 and fatty acid methyl esters
(FAME) standards were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Analytical grade
chloroform, methanol and n-hexane were obtained
from Merck (Darmstadt, Germany). Gases for
chromatography of 5.5 purity level were pur-
chased from AirLiquide (Poland).
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Isolation of cell membranes from erythrocytes.
Hemoglobin-free RBC membranes were pre-
pared by hypotonic hemolysis at 4°C in 10 mM
Tris with pH=7.4. Membranes were then isolated
by centrifugation (10.000 x g; 15 min) and washed
several times to eliminate hemoglobin residues ac-
cording to the method proposed by Graham
(GRAHAM 2006).
Lipid analysis
Total lipid extraction from erythrocyte mem-
branes was carried out with a solution of chloro-
form/methanol (2:1). The synthesis of FA methyl
esters of total lipids in the erythrocyte membranes
was carried out with 14 % BF3 in methanol. An in-
ternal standard, heptadecanoic acid, was used
throughout. The FA methyl esters were analyzed
using gas chromatography (Agilent 6890N). Chro-
matograph parameters were as follows: FID 260oC,
oven – start at 140oC and ramp up to 240oC. Col-
umn DB – 23 (60 m, 0.25 µm). Inlet temperature
250oC, split 40:1, injection 1 µl. FA methyl esters
were identified according to standards (Sigma-Al-
drich, Supelco, USA). The data were analyzed us-
ing ChemStation and Excel software. Results
were expressed in relative percentage of total FA.
We calculated total saturated FA (SFA), monoun-
saturated FA (MUFA), n-6 and n-3 PUFA, as well
as trans-FA. Additionally, we calculated the
n-3/n-6 ratio (GDULA-ARGASIÑSKA et al. 2015).
Statistics
All data are presented as means ± standard de-
viation (SD), or medians and interquartile ranges.
Differences between study groups were deter-
mined using one-way or multi-factor analysis of
variance including ANOVA with the Scheffé post
hoc test. Potential confounding factors such as
age, sex and BMI were included along with FA in
the multi-factor model.
Analysis of similarities between content of the
FA in RBC membranes of controls and CDI pa-
tients was also performed using clustering meth-
ods. Ward’s method with a Euclidean distance
matrix was used to group a set of objects in such a
way that objects in the same group are more simi-
lar to each other than to those in other groups. Clus-
ter analysis is a convenient multivariate method
which aims to classify grouping objects of similar
kind into respective categories on the basis of a set
of measured variables. Calculations were per-
formed using StatSoft, Inc. (2011), STATISTICA,
version 10 statistical package software, and statis-
tical significance was defined as á < 0.05.
Results
In all patients with CDI, elevated temperature
(37.5-39.8oC) and diarrhea were observed. On the
day of admission, patients had an average of
6 bowel movements per day and they all com-
plained of either abdominal pain or weakness. Sin-
gular episodes of vomiting (one to three) occurred
in a group of 5 patients. We excluded patients with
the severest CDI with poor prognosis, so none of
our patients died. 11 patients were treated with
metronidazole, 11 with vancomycin, and 8 pa-
tients were treated initially with metronidazole,
but due to intolerance or lack of proper improve-
ment, they were switched to vancomycin therapy.
The mean time of hospitalization after CDI diag-
nosis was 10.1 days (SD±4.2 days).
BothgroupshadnormalweightBMI(18.5-25kg/m2),
similar ages, and a typical Western diet. RBC FA
content in patients with CDI and controls are shown
in Table 1. After adjustment for age, sex and BMI
we did not observe significant changes between
adjusted and unadjusted multi-factor models.
The erythrocyte membrane SFA index (45.3%)
was higher and MUFA index (27.9%) was lower in
patients with CDI infection compared to the con-
trol group (SFA 41.5%, MUFA 30.4%). Total
RBC n-6 acids were significantly higher in the
CDI group compared to the control group (23.3%
and 16.9%, respectively, P=0.0001).
Total n-3 FA were significantly decreased in the
erythrocyte membranes of patients with CDI as
compared to the control group (4.5% and 10.4%,
respectively, P=0.0001). In the CDI group, we ob-
served small amounts of docosahexaenoic acid
(DHA). Eicosapentaenoic acid (EPA) content was
lower (1.0%) when compared to the control group
(3.6%, P=0.0001). The n-3/n-6 ratio was signifi-
cantly decreased (three-fold) in patients with CDI
(ratio 0.2) compared to the control group (ratio 0.6).
To determine the covariant behavior of the
measured variables, we analyzed variables to iden-
tify which best discriminate the FA profile in
erythrocyte membranes from controls and patients
with CDI (Fig. 1). Variables were separated into
three unique clusters. In the RBC of cluster 1 con-
trol group, 14:0, 16:1, 14:1, 15:0, 18:3 n-3, EPA
and 20:4n-6 FAs were present. Cluster 2 grouped
long-chain FAs (20:2n-6, 20:3n-6, 22:2n-6,
20:3n-3 and DHA). In cluster 3, the following FA
variants grouped together: 16:0 and 18:1 (Fig 1,
top). The distribution of variants was different in
the RBC of CDI patients when compared with the
control group. In cluster 1, 14:0, 14:1, 15:0 and n-3
FAs were dominant (18:3n-3, 20:3n-3 and EPA).
The cluster 2 grouping included 16:1, 18:0 and
18:2n-6. The cluster 3 group included 16:0, 18:1
and 20:4n-6 FAs (Fig. 1, bottom).
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Discussion
The impact of PUFA on the pathogenesis of sev-
eral chronic diseases has been studied, including
cardiovascular diseases, rheumatoid arthritis, neu-
rodegenerative, and neoplastic diseases (CALVIELLO
et al. 2013). The basis of our study was to assess
whether and how acute inflammation affects the
lipid composition of the cell membrane. Hypo-
thetically, this could have two basic implications:
FA could actively influence the course of acute in-
flammation, which has so far been demonstrated
only in the course of chronic inflammatory pro-
cesses, and the change in lipid composition of
erythrocyte membrane could be translated into
their proper functioning.
The acute inflammatory response is an organ-
ism’s defense to a damaging stimulus, the delicate
homeostasis between defensive pro-inflammatory
and suppressive anti-inflammatory responses, is
the basis of a successful reaction against an invad-
ing pathogen (HOFMANOVA et al. 2014). The im-
mune system uses both local and systemic
mechanisms in its response, both of which are ex-
tremely important, however the local response oc-
curring at the site of injury allows for a quick
defensive response. FA as a component of cell
membranes are almost always and immediately
present at the inflammatory site (CHAPKIN et al.
2007; HOFMANOVA et al. 2014). The effect of n-6
FA mainly results from the action of arachidonic
acid (AA) and their derivatives, and it is mainly
Table 1
Erythrocyte membrane fatty acids profile as a [%] of peak area in the controls (n=30) and
patients with CDI (n=30). Means ±SD (min-max).
Fatty acids Control CDI P
C14:0 myristic 3.0±2.0 (0.5-8.9) 3.7 ±2.1 (0.8-2.8)
C15:0 pentadecanoic 2.7±1.0 (0.6-3.5) 3.1 ±1.1 (1.0-3.2)
C16:0 palmitic 22.5±9.7 (3.2-49.2) 28.1±8.9 (19.0-27.0)
C18:0 stearic 13.3±6.8 (7.7-38.6) 10.4±4.6 (6.2-13.6) P=0.01
Total SFA 41.5±10.3(25.6-54.0) 45.3±10.6 (29.5-53.5)
C14:1n-5 myristoleic 2.6±1.0 (0.5-5.7) 1.8±0.6 (0.2-4.3)
C16:1c palmitoleic 2.8±1.6 (0.6-4.2) 6.0±2.3 (3.3-6.8) P=0.001
C18:1n-9c oleic 25.0±11.0 (13.8-29.4) 20.1±8.5 (14.2-27.0)
Total MUFA 30.4±11.5 (14.7-40.5) 27.9±8.2 (18.5-44.6)
C18:2n-6 linoleic 7.6± 3.4 (2.9-7.8) 6.1±2.3 (4.3-8.2)
C20:2n-6 cis 11,14eicosadienoic 0.9±0.2 (0.2-1.4) 0.1±0.0 (0.0-0.3) P=0.0001
C20:3n-6 dihomo-?-linolenic 1.3±0.6 (0.2-1.9) 0.1±0.0 (0.0-0.8) P=0.0001
C20:4n-6 arachidonic 6.1±1.9 (4.8-10.2) 16.9±5.4 (5.9-23.8) P=0.0001
C22:2n-6 cis-13,16-docosadienoic 1.0± 0.5 (0.6-1.8) 0.1±0.0 (0.0-0.5) P=0.0001
Total PUFA n-6 16.9±6.0 (5.9-18.1) 23.3±6.4 (11.6-35.1) P=0.0001
C18:3n-3 linolenic 3.9±0.9 (1.7-8.4) 0.7±0.5 (0.0-1.4) P=0.0001
C20:3n-3 cis11,14,17 eicosatrienoic 1.3±0.4 (0.4-1.9) 2.7±0.7 (0.0-2.9) P=0.0001
C20:5n-3 EPA 3.6±0.7 (1.4-5.7) 1.0±0.4 (0.1-1.8) P=0.0001
C22:6n-3 DHA 1.6±0.5 (0.5-2.6) 0.1±0.0 (0.0-0.7) P=0.0001
Total PUFA n-3 10.4±2.8 (8.3-15.4) 4.5±1.4 (2.0-6.2) P=0.0001
n-3/n-6 0.6±0.1 (0.5-0.9) 0.2±0.1 (0.0-0.3) P=0.0001
FA, fatty acids; MUFA, sum of mono-unsaturated FAs; n-3, sum of n-3 FAs; n-6, sum of n-6 FAs; n-3/n-6 FAs ratio; PUFA,
polyunsaturated fatty acids; SFA, sum of saturated FAs; UNSFA, sum of unsaturated FAs.
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Fig. 1. Cluster analysis of the FA profile in RBC membranes from controls (top) and from CDI patients (bottom). Data were
segregated into 3 unique clusters of variables by hierarchical cluster analysis.
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pro-inflammatory. Conversely, n-3 FA display
strong anti-inflammatory and pro-resolving ef-
fects, particularly the newly discovered resolvines
and protectins which work as “stop-signals” ar-
resting the inflammatory process (KHAN et al.
2014; GDULA-ARGASIÑSKA et al. 2015).
Some disorders with a more pronounced and
clearly-defined inflammatory character such as
chronic obstructive pulmonary disease, asthma
and Crohn’s disease have become more prevalent
in most Western societies in the past decades, in
parallel with a greatly increased intake of n-6
PUFA. Clear associations between the risk of their
onset and a shifted balance of n-6 PUFA and n-3
PUFA intake are lacking, but many investigators
have recognized the potential of long-chain n-3
PUFA in dampening excessive inflammation in
most inflammatory diseases and conditions
(SIJBEN & CALDER 2007).
To the best of our knowledge, our study is the
first that assesses FAs in acute infectious colitis
among humans, and current scientific knowledge
of the influence of PUFA on acute colitis comes
only from animal studies. It was demonstrated that
substitution of linoleic acid (LA) with long chain
n-3 PUFA protected the colonic mucosa in dextran
sulfate sodium (DSS) induced colitis (TYAGI et al.
2014). It was also shown that endogenously pro-
duced n-3 PUFA in transgenic fat-1 mice, decreases
cyclooxygenase 2 (COX-2) and prostaglandin E2
(PGE2,) expression, thus fulfilling a protective role
in DSS-colitis (GRAVAGHI et al. 2011). As men-
tioned above some studies showed the protective
effect of n-3 PUFA in experimental colitis, but
also a few studies have failed to show this. For ex-
ample it was demonstrated that a diet with 6% fish
oil and 1% corn oil (n-6/n-3 ratio 0.17) aggravated
colitis (WOODWORTH et al. 2010). In mice, a diet
rich in n-6 PUFA strengthened the immunologic
response during E. coli infection (WAN & GRIMBLE
1987), whereas a diet rich in n-3 FA but with a de-
creased amount n-6 decreased the intensity of coli-
tis in interleukin 10 (IL-10) knockout mice (MANE
et al. 2009). It appears as though this game of ap-
propriate ratio of n-3/n-6 has a significant impact
on the ideal response to a stimulus between the
strong initial inflammatory response and its subse-
quent arrest. However a diet rich in n-3 PUFA, via
its anti-inflammatory effect, may have a negative
effect on the antimicrobial response. n-6 PUFA
augments colitis, but prevents infection-induced
systemic inflammation. In contrast, n-3 PUFA
supplementation reverses the effects of the n-6
PUFA diet but impairs infection-induced re-
sponses resulting in sepsis (GHOSH et al. 2013).
In our study, we observed significant changes in
the FA profile of erythrocyte cell membranes in
patients with CDI. The most significant changes
were found in n-6 and n-3 FA, which suggests an
intense inflammatory reaction within an organism
during infection. We observed less than half the
level of n-3 FA in patients with CDI compared to
patients in the control group and a small amount of
DHA. This may suggest a deficit of n-3 FA in the
bodies of patients with CDI. This allows us to hy-
pothesize that anti-inflammatory n-3 FA may
serve as pro-resolving mediators during CDI in-
fections. The n-3/n-6 ratios in RBC membranes
were significantly lower (three-fold) in patients
with CDI than in the control. This lower ratio in
CDI patients is a reflection of ongoing inflamma-
tion in these patients and indicates the role of
PUFA in the inflammation.
The subsequent question is how, in the acute in-
flammatory process, such a quick and dramatic
change such as the change in membrane lipid com-
position seen in our study could occur. Mature red
cells cannot synthesize membrane lipids de novo.
Therefore, lipid exchange and acylation of FA is
the only known possible mechanism for phos-
pholipid repair and renewal. The exchange rate of
outer bilayer phospholipids with the phospholip-
ids of lipoproteins in plasma is slow (a turnover
time of 5 days) while phospholipids in the inner
leaflet of the bilayer are essentially nonexchange-
able. However free cholesterol in red cell mem-
branes exchanges readily with the unesterified free
cholesterol in plasma lipoproteins (a half-life of 7 h)
(CHAPKIN et al. 2007). Taking into account that
the blood of patients with CDI in our test group
was taken at the beginning of the infection, the
change in the RBC cell membranes observed in
this study must be different from the classically de-
scribed renewal of membrane lipids. This warrants
further study.
The statistically different FA compositions of
RBC membranes may play a role in rheological
patterns of RBC during CDI. In an earlier study,
we observed significant changes in the hemorheo-
logic characteristics of RBC. Alterations in RBC
membranes are one of the important factors re-
sponsible for these characteristics. We found a sta-
tistically significant increase in Aggregation Index
(AI) and alterations in RBC Elongation Index (EI)
in the group of patients with CDI (CZEPIEL et al.
2014). The FA pattern of membrane phospholipids
is suggested to affect membrane fluidity and
epithelial barrier function as a result of membrane
FA unsaturation. RBC membranes are composed
of 35.1% lipids, when disregarding water content
this is 43.6% lipids (YAWATA 2003). The state of
saturation of FA, and the length of acyl chains af-
fect the degree of membrane fluidity. When the de-
gree of desaturation increases, the packing of
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hydrophobic tails in the core of the bilayer is dis-
rupted. Differences in lipid composition may have
important implications for the membrane proper-
ties of the RBC. The significant changes in FA ob-
served in our study might be one of the factors
important in RBC deformability changes during
acute infection. The shape of RBC, which also de-
pends on the state of the membrane lipids, is an-
other important factor influencing deformability.
Strongly charged amphipathic compounds i.e.
phospholipids, can cause echinocytosis due to
their trapping in the outer leaflet of the lipid bilayer
by a fixed charge (YAWATA 2003).
Oxidative stress in the hyperinflammatory state
during CDI may also cause RBC membrane
changes, including cytoskeleton rearrangement as
well as oxidation and loss of lipid asymmetry.
Moreover, RBCs exposed to both endogenous and
exogenous sources of reactive oxygen and nitro-
gen species undergo not only mechanical altera-
tion such as decreased deformability but also
accumulation of oxidative damage products such
as lipid oxidation products (BUTTARI et al. 2015).
For example Shiga toxin-producing Escherichia
coli infections cause hemolytic uremic syndrome,
characterized by thrombotic microangiopathy that
leads to hemolytic anemia (GOMEZ et al. 2013).
Hemolytic uremic syndrome (HUS) often follows
infectious diarrhea. A variety of enteric pathogens
including Salmonella species, Escherichia coli
O157:H7, and Campylobacter jejuni are causative
agents of HUS (KESHTKAR-JAHROMI & MOHEBTASH
2012). The association between 658240462 Clos-
tridium difficile and HUS is not as obvious. There
are a few cases reported from 1977 which indicate
that HUS is a possible, but very rare, complication
of CDI (TOCHEN & CAMPBELL 1977; MBONU et al.
2003; KESHTKAR-JAHROMI & MOHEBTASH 2012;
ALVARADO et al. 2014). The mechanism of this
process is not understood but it is known that
C. diff. toxins, due to Rho inactivation, disrupt the
cytoskeleton (GOUDARZI et al. 2014). We hy-
pothesize that C. diff. is capable of hemolytic im-
pacts of varying severity, with consequent damage
to the erythrocyte membrane and subsequently
leads to the observed disturbances in the lipid com-
position of RBCs. Only in small numbers of cases
is this mechanism severe enough to cause the de-
velopment of HUS, which would explain the small
number of CDI-associated HUS cases reported.
Taken together, oxidative stress may contribute
to the senescence and oxidation of RBCs. This
suggests that in patients with CDI, the lifetime of
the erythrocytes might be reduced either by oxida-
tive stress or by increased cell hemolysis.
In conclusion, erythrocyte membrane FA com-
position in CDI patients is reported for the first
time in this study. We discovered a significant de-
crease in the levels of n-3 FA as well as a signifi-
cant increase in n-6 FA in patients with CDI.
Because the membrane FA content effects mem-
brane fluidity, these findings are worthy of further
investigation. The deficit of n-3 FA in RBC cell
membranes in patients with CDI may suggest a po-
tential therapeutic role of n-3 PUFAs; that they hy-
pothetically could be used as nutraceuticals to
modify the composition and organization of cell
membranes to selectively initiate a change in their
fluidity and function. The data obtained may be
useful in further studies of the biochemistry of lip-
ids in patients with acute infection.
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